Codexis Inc CDXS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CDXS is a good fit for your portfolio.
News
-
Codexis to Report Second Quarter 2024 Financial Results on August 8
-
Codexis Finalizes Purchase Agreement with Crosswalk Therapeutics for Gene Therapy Assets
-
Codexis to Participate in Jefferies Global Healthcare Conference
-
Codexis to Participate in TD Cowen 2nd Annual Sustainability Week
-
Codexis Presents Groundbreaking Enzymatic Synthesis Data at TIDES USA Annual Meeting
-
Codexis Reports First Quarter 2024 Financial Results
-
Codexis Shares Up 31% on Roche Licensing Agreement
Trading Information
- Previous Close Price
- $3.65
- Day Range
- $3.62–3.76
- 52-Week Range
- $1.45–4.91
- Bid/Ask
- $3.50 / $3.74
- Market Cap
- $261.06 Mil
- Volume/Avg
- 462,303 / 459,271
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.44
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 174
- Website
- https://www.codexis.com
Comparables
Valuation
|
Metric
|
CDXS
|
TIHE
|
MRVI
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 162.41 |
Price/Book Value | 3.29 | — | 2.96 |
Price/Sales | 3.44 | — | 4.41 |
Price/Cash Flow | — | — | 87.53 |
Price/Earnings
CDXS
TIHE
MRVI
Financial Strength
|
Metric
|
CDXS
|
TIHE
|
MRVI
|
|---|---|---|---|
Quick Ratio | 3.43 | — | 10.19 |
Current Ratio | 3.71 | — | 11.32 |
Interest Coverage | — | — | 13.71 |
Quick Ratio
CDXS
TIHE
MRVI
Profitability
|
Metric
|
CDXS
|
TIHE
|
MRVI
|
|---|---|---|---|
Return on Assets (Normalized) | −26.96% | — | −0.31% |
Return on Equity (Normalized) | −45.98% | — | −1.28% |
Return on Invested Capital (Normalized) | −37.18% | — | 0.45% |
Return on Assets
CDXS
TIHE
MRVI
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Ckkfkgfb | Ljcl | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Rnsclqgx | Zjygz | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Pwcqpfvg | Hqlht | $118.7 Bil | |||
| Moderna Inc
MRNA
| Nlfmnkgs | Lphk | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Lqmskbng | Rbdxxm | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Qyjwsgst | Ysx | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Mymrcsd | Ych | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Mgwcshgcv | Sqcsbfb | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Fqgdsdjf | Bmwj | $15.0 Bil | |||
| Incyte Corp
INCY
| Tymcwvtlw | Gpytct | $13.5 Bil |